Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Canadian National Railway $750 million notes offering
We advised the company on the investment-grade debt offering
Janus Henderson $400 million senior notes offering
The investment-grade notes are due 2034
CK Hutchison Holdings $1 billion notes offering
We advised CK Hutchison Holdings on the investment-grade notes offering
Norwegian Cruise Line $315 million senior notes offering
The high-yield notes are due 2030
Bunge Global $2 billion senior notes offering
The investment-grade notes are due 2028, 2029 and 2034
Province of Ontario $2 billion global bond offering
The investment-grade bonds are due 2029
MBX Biosciences $188 million IPO
The shares are listed on the Nasdaq Global Select Market
W.W. Grainger $500 million notes offering
The investment-grade notes are due 2034
Terns Pharmaceuticals $173 million stock and pre-funded warrants offering
The shares are listed on the Nasdaq Global Select Market
Ionis Pharmaceuticals $500.3 million follow-on offering
The shares are listed on the Nasdaq Global Select Market